iifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Lupin names Christoph Funke as new Chief Technical Officer

19 Mar 2024 , 11:06 AM

Lupin Ltd, a global pharmaceutical company, has hired Christoph Funke to the newly formed role of Chief Technical Operations Officer. Funke joins Lupin with over 30 years of experience in global pharmaceutical production, supply chain management, and technical operations, according to the business.

He will be located in Mumbai and would be in charge of Lupin’s technical operations, which include production, supply chain, and procurement, according to the announcement.

Funke has held executive positions at Fresenius Kabi and Strides Pharma Science.

The press release stated that Funke, in his leadership positions, has overseen extensive technical operations and manufacturing networks spanning 27 locations across 19 countries. He managed production worth more than $2 billion and supervised teams comprising over 12,500 employees. Funke graduated with an engineering degree from South Westphalia University of Applied Sciences, Germany.

“We are thrilled to have Christoph join our executive leadership team. His outstanding achievements and broad expertise in manufacturing, supply chain management, and technical operations make him a valuable asset as we strive to further our mission of enhancing the well-being of patients worldwide,” stated Lupin’s CEO Vinita Gupta and Managing Director Nilesh Gupta in the company’s announcement.

The US Food and Drug Administration (US FDA) examined the company’s production plant in Aurangabad from March 6 to March 15, 2024, and issued Form-483 with one observation.

The company expressed confidence in resolving the issue raised by the USFDA promptly. They emphasized their commitment to prioritizing quality and compliance, ensuring adherence to CGMP quality standards at all their facilities.

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • Lupin
  • Lupin News
  • Lupin Stock
  • Lupin Updates
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.